CLASS II ONGOING Drug recall · Reported 11 Nov 2026 · FDA Enforcement Report
Metoprolol Tartrate Tablets, USP, 50 mg recalled by Advagen Pharma
Advagen Pharma is recalling Metoprolol Tartrate Tablets, USP, 50 mg per, distributed nationwide in the US. The recall was initiated on 27 Oct 2026 and the FDA has classified it as Class II.
Check your package
Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.
Recall details
- Recall number
- D-0182-2027
- FDA event ID
- 100234
- Recalling firm
- Advagen Pharma, East Windsor, NJ
- Brand
- Metoprolol Tartrate
- Manufacturer
- Advagen Pharma Ltd
- Classification
- Class II
- Status
- Ongoing
- Recall initiated
- 27 Oct 2026
- FDA classified
- 10 Nov 2026
- Reported
- 11 Nov 2026
- Type
- Voluntary: Firm initiated
- Customers notified by
- Letter
- Reason category
- Other Reasons
- Drug class
- Blood Pressure Medication
Timeline
| 27 Oct 2026 | Recall initiated by company | |
| 10 Nov 2026 | Classified by FDA | +14 days |
| 11 Nov 2026 | Published in enforcement report | +1 day |
Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.
Reason for recall
Presence of Foreign Tablets/Capsules
Product as listed by the FDA
Metoprolol Tartrate Tablets, USP, 50 mg, 1,000 Tablets per bottle, Rx Only, Distributed by: Advagen Pharma Ltd., East Windsor, NJ 08520, USA. NDC: 72888-210-00.
Where it was distributed
U.S. Nationwide
Questions about this recall
Why was it recalled?
Presence of Foreign Tablets/Capsules
Which lots are affected?
Batch#: 2611C065A1: Expiry: 05/2028
Where was it sold?
U.S. Nationwide
What should I do if I have it?
Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.
What does Class II mean?
Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.
Read the official FDA notice · Source record retrieved 17 Nov 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.
Other Metoprolol recalls
All 41| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS II | Metoprolol Succinate Extended-Release Tablets, USP, 25 mg* recalled | Ascend Laboratories | Potency & Assay | Nationwide |
| Drug | CLASS II | Metoprolol Succinate Extended-Release Tablets recalledMetoprolol Succinate | Teva Pharmaceuticals USA | Potency & Assay | Nationwide |
| Drug | CLASS II | Metoprolol Succinate Extended-Release Tablets, 200 mg recalledMetoprolol Succinate | Teva Pharmaceuticals USA | Potency & Assay | Nationwide |
| Drug | CLASS II | Metoprolol Succinate Extended-Release Tablets, 25 mg bottles recalledMetoprolol Succinate | Teva Pharmaceuticals USA | Potency & Assay | Nationwide |
| Drug | CLASS II | Metoprolol Succinate Extended-Release Tablets, 50 mg bottles recalledMetoprolol Succinate | Teva Pharmaceuticals USA | Potency & Assay | Nationwide |